Inspire Medical Systems, Inc. Announces Departure of Chief Financial Officer

Company Overview - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [4] - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [4] Leadership Change - Chief Financial Officer Rick Buchholz will step down effective December 31, 2025, to pursue other professional opportunities, but will remain in a financial advisory role until February 28, 2026, to ensure a smooth transition [1][2] - Buchholz has been with the company since 2014 and has played a significant role in its growth, including increasing revenue from $4 million to over $800 million in 2024 [2] Financial Guidance - The company reaffirms its full-year 2025 revenue guidance of $900 to $910 million, with a gross margin guidance of 84% to 86% and diluted net income per share guidance of $0.40 to $0.50 [3]